Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
2264 1 |
Ultima descărcare din IBN: 2020-03-26 12:56 |
SM ISO690:2012 JIMBEI, Paulina, DEATISIN, Victor, PANTEA, Valeriu, RUDIC, Valeriu, SPÎNU, Constantin, CEBOTARESCU, Valentin. Combined Tamiflu and BioR Treatment in Patients with H1N1 Influenza. In: Curierul Medical, 2011, nr. 3(321), pp. 32-35. ISSN 1875-0666. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Curierul Medical | ||||||
Numărul 3(321) / 2011 / ISSN 1875-0666 | ||||||
|
||||||
Pag. 32-35 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
A comparative study of combined Tamiflu and BioR treatment has been performed in 22 patients with (H1N1) influenza A (the experimental lot) and
17 patients (the control lot) in which only the Tamiflu was administered. The diagnosis of influenza A (H1N1) was confirmed using PCR. The clinical
symptomatology varied amongst patients, but the most frequent symptoms were fever, throat pains asthenia, myalgias, hyperemia of the pharyngeal
isthmus, dry cough, harsh respiration, chills, and nasal congestion. Tamiflu was administered in a dose of 75 mg orally twice a day, in the morning and
in the evening; the average length of treatment was 5 days. BioR was administered to 16 patients as 5.0 mg orally, twice a day, and to 6 patients as1 mg
IM, twice a day; average length of treatment was 5 days for all groups. The control group received Tamiflu only, the same dosage as the study group.
The average length of treatment was 6.0 days. Comparing the length of the symptoms in the experimental group to that in the control group, we found
that duration of symptoms reflecting the influence of the central nervous system in the experimental group was on average 5.0 days as compared to 6.6
days in the control group. Similarly, duration of symptoms affecting the respiratory system in the experimental group was 3.8 days and in the control
group 5.3 days. We conclude that the Tamiflu and BioR treatment in patients with influenza A (H1N1) was beneficial and contributed to the decrease
of symptom duration as compared to the group of patients treated with Tamiflu alone. |
||||||
Cuvinte-cheie A (H1N1) influenza, Tamiflu, BioR, treatment |
||||||
|